Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
NurExone Biologic ( (TSE:NRX) ) has issued an announcement.
NurExone Biologic Inc. has announced progress in its clinical-readiness strategy by evaluating potential Israeli partners for small-scale GMP manufacturing of its lead candidate, ExoPTEN, in preparation for future First-in-Human use, pending regulatory approval. The company has reported new scientific data showing superior biological activity of its exosomes compared to commercially available ones, reinforcing confidence in their therapeutic potential and supporting the planned manufacturing and clinical efforts.
More about NurExone Biologic
NurExone Biologic Inc. is a preclinical-biotechnology company focused on developing exosome-based therapies for central nervous system injuries. The company’s primary product, ExoPTEN, is being developed for acute spinal cord and optic nerve injuries, with a market focus on advancing therapeutic options for these conditions.
Average Trading Volume: 57,602
Technical Sentiment Signal: Hold
Current Market Cap: C$49.7M
See more insights into NRX stock on TipRanks’ Stock Analysis page.